A week after naming a full-time CFO, CytRx said that it has expanded its management team by three people, all of whom come from CEO Steve Kriegsman’s investment firm, The Kriegsman Group.
CytRx said that it has tapped Ed Umali as director of operations, David Haen as director of business operations, and Carolyn French as director of communications.
French’s position at CytRx is on a full-time basis, while Umali and Haen are expected to continue to provide certain services to The Kriegsman Group on a limited basis.
Following its 2002 merger with Global Genomics, CytRx was stripped down by Kriegsman and set on a new course: to develop therapeutics based on RNAi. Part of that overhaul included building a new management team, a task Kriegsman said has now completed.
“All of the slots have been filled,” he said. “We’ve got a team in place to do whatever we need to do.”
CytRx now has nine employees, he said. This does not include the roughly 10 UMass researchers conducting work for the company under a sponsored research agreement.